Century Therapeutics (IPSC) risk factors, FY2024 10-K

Risks related to our financial position and capital requirements

1. 01Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
2. 02We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future
3. 03We have never generated revenue from product sales and may never achieve or maintain profitability
4. 04We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts
5. 05Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
6. 06Our common stock is listed on The Nasdaq Global Select Market, which imposes continued listing requirements with respect to listed securities, including a minimum bid price requirement
7. 07Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
8. 08Changes in tax law may adversely affect us or our investors
9. 09Our Option Agreement with Bayer HealthCare LLC may require us to sell certain of our product candidates, which may limit the value we could generate from our product candidates
10. 10Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and stock price

Risks related to our business and industry

1. 11We are early in our development efforts. Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval, and ultimately commercialize them
2. 12Our business is highly dependent on the success of our lead product candidate, CNTY-101 and our other product candidates
3. 13for such product candidates in our pipeline could be significantly impaired, which could materially adversely affect our business, financial condition, results of operations, and growth prospects
4. 14Our business depends upon the success of our iPSC-derived allogeneic cell therapy platforms
5. 15Utilizing CAR-iNK and CAR-iT cells represents a novel approach to immuno-oncology treatment of cancer and autoimmune diseases, and we must overcome significant challenges in order to develop, commercialize, and manufacture our product candidates
6. 16We have not yet demonstrated long-term stability of cryopreserved CAR-iNK cells
7. 17Gene-editing is a rapidly developing technology, and our success is dependent upon our ability to effectively utilize this technology in our product candidates and implement future technological advancements in gene-editing
8. 18Although we believe CAR-iNK and CAR-iT based therapies do not require further modification to avoid the risk of graft versus host disease, or GvHD, the gene-editing of our product candidates utilizing CAR-iNK and CAR-iT cells may not be successful in limiting the risk of GvHD or premature rejection by patients
9. 19Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
10. 20such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA
11. 21Preclinical and clinical development involve a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates
12. 22Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
13. 23Beyond CNTY-101, we may not be able to file our INDs or CTAs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or other global health authorities may not permit us to proceed
14. 24We intend to study our product candidates in patient populations with significant comorbidities that may result in deaths or serious adverse events or unacceptable side effects and require us to abandon or limit our clinical development activities
15. 25We may experience difficulties identifying and enrolling patients in our clinical trials. Difficulty in enrolling patients could delay or prevent clinical trials of CNTY-101 or our other product candidates
16. 26CNTY-101 and our other product candidates may cause adverse events or undesirable side effects that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any
17. 27Public opinion and scrutiny of cell-based immuno-oncology therapies for treating cancer or immune-related disorders, or negative clinical trial results from our cell-based therapy competitors, may impact public perception of our company and product candidates, or impair our ability to conduct our business
18. 28Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing
19. 29If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed
20. 30longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others
21. 31We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates
22. 32We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
23. 33We may explore strategic collaborations that may never materialize or we may be required to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators

Risks related to manufacturing

1. 34The manufacture and distribution of our iPSC-derived cell product candidates is complex and subject to a multitude of risks. These risks could substantially increase our costs and limit the clinical and commercial supply of our product candidates
2. 35We rely on third parties for the manufacture of some of our product candidates for development, although we now operate our own manufacturing facility for the production of certain of our product candidates
3. 36Delays in commissioning and receiving regulatory approvals for our manufacturing facilities could delay our development plans and thereby limit our ability to generate revenues

Risks related to commercialization of our product candidates

1. 37If we are unable to successfully commercialize CNTY-101 or any of our other product candidates for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed
2. 38We face significant competition, and if our competitors develop product candidates more rapidly than we do or their product candidates are more effective, our ability to develop and successfully commercialize products may be adversely affected
3. 39We expect to face uncertainty regarding the pricing of our existing product candidates and any other product candidates that we may develop, and for which we may receive approval
4. 40The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new products could limit our product revenues
5. 41Even if we obtain regulatory and marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight
6. 42materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws
7. 43Even if we receive marketing approval for CNTY-101 or our other product candidates, we may not achieve broad market acceptance
8. 44Even if we receive marketing approval for CNTY-101 or our other product candidates in the United States, we may never receive regulatory approval to market CNTY-101 or our other product candidates outside of the United States
9. 45We may be unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell CNTY-101 or our other product candidates, if approved
10. 46If the market opportunities for our product candidates for which we receive marketing approval are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer
11. 47Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide

Risks related to employee matters, managing growth and other risks related to our business

1. 48We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
2. 49We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth
3. 50Any pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our drug candidates
4. 51We are subject to various foreign, federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition
5. 52Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
6. 53If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired
7. 54We, or our CMOs or suppliers, may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly
8. 55If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
9. 56We may be unable to adequately protect our or our vendors’ information systems from cyberattacks or other incidents, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure
10. 57Our employees and independent contractors, including principal investigators, CROs, consultants, and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
11. 58Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information and personal data
12. 59The increasing use of social media platforms presents new risks and challenges

Risks related to our intellectual property

1. 60We do not currently own issued patents relating to some of our product candidates
2. 61If any of our license agreements with FCDI are terminated, we could lose our rights to key components enabling our iPSC-derived allogeneic cell therapy platforms
3. 62We may not be successful in obtaining or maintaining necessary intellectual property rights in the future for the development of CNTY-101 and our other product candidates
4. 63If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business
5. 64Our success depends on our ability to obtain, maintain, protect, and enforce our intellectual property and our proprietary technologies
6. 65If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
7. 66The patent protection and patent prosecution for some of our product candidates may be dependent on third parties
8. 67Intellectual property rights do not necessarily address all potential threats to our competitive advantage
9. 68Should any of these events occur, it could significantly harm our business, results of operations, and prospects
10. 69The intellectual property landscape around gene-editing technology is highly dynamic, and third parties may initiate and prevail in legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights
11. 70We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
12. 71Changes in United States patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect CNTY-101 and our other product candidates
13. 72We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
14. 73Patent terms may be inadequate to protect our competitive position on CNTY-101 and our other product candidates for an adequate amount of time
15. 74If we do not obtain patent term extension for CNTY-101 and our other product candidates, our business may be materially harmed
16. 75We may not be able to protect our intellectual property rights throughout the world
17. 76Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
18. 77If we are unable to protect the confidentiality of our trade secrets, our business, and competitive position would be harmed
19. 78We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks related to our common stock

1. 79The trading price of the shares of our common stock has been highly volatile, and purchasers of our common stock could incur substantial losses
2. 80We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock
3. 81Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
4. 82Our executive officers, directors, principal stockholders, and affiliates have the ability to exercise significant control over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control
5. 83We are an emerging growth company and a “smaller reporting company”, and the reduced disclosure requirements applicable to emerging growth companies and “smaller reporting companies” may make our common stock less attractive to investors
6. 84We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives
7. 85If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
8. 86Provisions in our corporate charter documents and under Delaware law could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management
9. 87We could be subject to securities class action litigation